** U.S.-listed shares of heart-valve maker Anteris Technologies AVR.O jump ~40% to $8.04 after hours after it unveils proposed stock offering, Medtronic MDT.N investment

** Co, whose principal executive offices are in Australia, announces $200 mln stock offering

** In addition, it agreed to sell to MDT up to $90 mln of stock in private placement, subject to minimum purchase of 16% and maximum purchase of 19.99% of its outstanding shares after the offering

** Anteris says plans to use net offering proceeds from both financings for ongoing recruitment and study execution of the DurAVR Transcatheter Heart Valve global trial for patients with severe aortic stenosis (the "PARADIGM Trial") and expansion of manufacturing capabilities, among other uses

** Barclays, Wells Fargo and Cantor Fitzgerald joint bookrunners

** Co has ~41.2 mln shares outstanding for roughly $240 mln market cap

** AVR shares closed up 12.5% at $5.75 on Tues, up ~15% to begin 2026. They lost ~11% last year

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))